Oncology experience

Facing the future with over 25 years of experience.

The financial burden of cancer

In 2010, the total spending for cancer care in the U.S. was reported to be around $125 billion and this continues to grow.1 As cancer care spending grows, so does patient cost-sharing. A 2017 report found that the average per-patient out-of-pocket costs for the first year following a cancer diagnosis were between $3,600 and $5,500 depending on cancer type, treatment required and insurance coverage.1 On top of this, annual premium contributions averaged between approximately $1,100 for single coverage and over $5,000 for family coverage in 2016. Additional costs such as travel expenses or loss of income further add to the financial burden for patients.1

It is clear that a cancer diagnosis can translate into significant spending that may continue over many years.1

The role of biosimilars in oncology

In their 2018 statement on biosimilars, the American Society of Clinical Oncology (ASCO) acknowledged that biosimilars will play an important role in the future care of patients with cancer and will improve access to medicines.2 The growing availability of oncology biosimilars could help to provide more treatment options, increase access to life-saving medicines and potentially lower treatment costs for both patients and payers.3

As of June 2021, there are 29 FDA-approved biosimilar products in the U.S., many of which are utilized in oncology or supportive care for patients with cancer.4,5 With increased experience and adoption of oncology biosimilar products the substantial savings versus the reference products will also continue to increase.6

Fresenius Kabi in oncology

At Fresenius Kabi we have one of the most comprehensive, non-branded oncology portfolios in the industry and have been supplying the U.S. with oncology medicines for more than a quarter of a century.

We currently supply more than 60 oncology drugs, and over 80 different chemotherapy regimens are supported by at least one Fresenius Kabi product. There are 35 chemotherapy regimens that are supported entirely by Fresenius Kabi products. And our pipeline continues to grow, with over 20 oncology products currently in development, including biosimilars and generics.

Fresenius Kabi oncology products are used in many different cancer types including:

References

  1. Dieguez G, et al. https://www.milliman.com/en/insight/2017/a-multi-year-look-at-the-cost-burden-of-cancer-care. Published 2017. Accessed May 5, 2021.
  2. Lyman GH, et al. American society of clinical oncology statement: Biosimilars in oncology. J Clin Oncol. 2018;36(12):1260-1265.
  3. FDA. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars. Published 2020. Accessed May 5, 2021.
  4. FDA. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Published 2020. Accessed May 5, 2021.
  5. Lyman GH. How biosimilars will impact costs and care in oncology. Clin Adv Hematol Oncol. 2019;17(10):544-547.
  6. Tilleul PR, et al. Introduction of biosimilar pegfilgrastim in France: Economic analysis of switching from originator [published online ahead of print 2020 Oct 6]. J Oncol Pharm Pract. 2020:1078155220962208.
Info

Looking for more information?

If you would like to know more about Fresenius Kabi and our unique approach to biosimilars, please get in touch.

Contact Us
Fresenius Kabi

Fresenius Kabi AG © June 2021 1702-BIOS-08-05/21